Skip to main content
    T

    Tectonic Therapeutic, Inc. (TECX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.98
    -0.16 (-0.76%)

    Market Cap: $413.27M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Tectonic Therapeutic, Inc. (TECX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Tectonic Therapeutic reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$74.15M, operating cash flow was -$60.08M and free cash flow was -$60.29M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$21.35M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $84.04M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$63.49M$41.36M$36.97M$72.19M$83.11M$87.24M$54.97M$35.09M$15.19M$2.66M
    Operating income-$84.04M-$58.02M-$44.65M-$105.43M-$118.84M-$120.23M-$75.81M-$46.24M-$18.39M-$4.63M
    Net income-$74.15M-$57.98M-$42.82M-$105.89M-$119.13M-$119.71M-$72.97M-$46.36M-$18.65M-$4.66M
    EBITDA-$82.78MN/A-$41.52M-$104.15M-$117.50M-$119.22M-$75.05MN/AN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0N/A$0$0$0-$508.00K$0$0$0-$373.00K
    Operating income-$23.46M-$24.22M-$27.30M-$21.52M-$21.89M-$22.33M-$18.30M-$13.99M-$19.64M-$11.42M-$12.97M$1.32M
    Net income-$21.35M-$22.29M-$25.24M-$19.23M-$19.04M-$19.98M-$15.91M-$12.37M-$17.72M-$12.67M-$15.22M$2.64M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.23M by $252.56M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$261.04M$152.91M$39.40M$103.95M$203.84M$271.23M$200.51M$133.48M$7.02M$5.40M
    Current assets$257.36M$146.86M$30.88M$99.96M$199.15M$267.24M$195.70M$130.02M$6.31M$5.38M
    Cash and equivalents$253.80M$141.24M$28.77M$92.56M$189.57M$259.68M$187.04M$126.30M$5.96M$5.36M
    Total liabilities$9.71M$12.13M$43.41M$28.58M$34.36M$16.89M$14.50M$11.29M$3.66M$979.00K
    Short-term debt$1.23M$2.78M$1.82M$1.45M$355.00KN/AN/AN/AN/AN/A
    Long-term debtN/AN/AN/A$15.28M$14.95MN/AN/AN/AN/AN/A
    Shareholder equity$251.33M$140.78M-$84.64M$75.37M$169.48M$254.34M$186.01M$122.18M-$23.14M$4.42M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$243.86M$237.03M$246.58M$261.04M$277.00M$295.31M$314.83M$152.91M$168.72M$193.91M$92.35M$39.40M
    Total liabilities$14.54M$13.19M$16.16M$9.71M$9.47M$11.55M$13.79M$12.13M$18.36M$27.54M$3.51M$124.03M
    Cash and equivalents$234.67M$227.07M$236.89M$253.80M$268.44M$287.38M$306.25M$141.24M$159.09M$185.12M$90.48M$28.77M
    Shareholder equity$229.32M$223.85M$230.42M$251.33M$267.53M$283.77M$301.04M$140.78M$150.36M$166.37M$88.84M-$84.64M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$60.08M-$59.08M-$40.68M-$97.21M-$98.03M-$98.80M-$67.67M-$37.65M-$16.38M-$3.31M
    Capital expenditures$208.00K$156.00K$279.00K$267.00K$2.46M$1.18M$1.58M$1.83M$383.00K$0
    Free cash flow-$60.29M-$59.24M-$40.96M-$97.47M-$100.49M-$99.98M-$69.25M-$39.48M-$16.77M-$3.31M
    Investing cash flow-$138.00K-$156.00K-$279.00K-$267.00K-$2.46M-$1.18M-$1.58M-$1.83M-$383.00K-$24.00K
    Financing cash flow$173.35M$171.71M$33.75M$262.00K$30.37M$172.62M$129.99M$160.29M$17.37M$8.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$14.91M-$21.45M-$18.41M-$14.46M-$17.82M-$14.72M-$13.08M-$16.82M-$19.60M-$13.38M-$9.27M-$11.66M
    Capital expendituresN/A$79.00K$19.00K$27.00K$181.00K$27.00K$27.00K$3.00K$153.00K$4.00K$4.00K$50.00K
    Free cash flowN/A-$21.53M-$18.43M-$14.49M-$18.00M-$14.75M-$13.11M-$16.82M-$19.76M-$13.39M-$9.28M-$11.71M
    Last 12 quarters

    Frequently Asked Questions About TECX

    What is Tectonic Therapeutic's annual revenue?

    Tectonic Therapeutic reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Tectonic Therapeutic profitable?

    No. Tectonic Therapeutic reported net income of -$74.15M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does TECX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$60.08M minus capital expenditures of $208.00K produced free cash flow of -$60.29M.

    How much debt does Tectonic Therapeutic have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.23M and cash and equivalents of $253.80M.